Mont-Saint-Guibert  Belgium - Celyad (Euronext Brussels and Paris  and NASDAQ: CYAD)  a pioneer in the discovery and development of CAR-T cell therapies  today announces exciting early clinical results of the first dose-level in the hematological arm of its THINK trial (THerapeutic Immunotherapy with CAR-T NKG2D)